Protective effects of bisoprolol against acute exacerbation in moderate-to-severe chronic obstructive pulmonary disease

Akihiko Taniguchi, Nobuaki Miyahara, Naohiro Oda, Daisuke Morichika, Eiki Ichihara, Isao Ozed, Yasushi Tanimoto, Hirohisa Ichikawa, Utako Fujii, Mitsune Tanimoto, Arihiko Kanehiro, Katsuyuki Kiura

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure.

Original languageEnglish
Pages (from-to)453-457
Number of pages5
JournalActa Medica Okayama
Volume71
Issue number5
Publication statusPublished - 2017

Fingerprint

Bisoprolol
Pulmonary diseases
Chronic Obstructive Pulmonary Disease
Heart Failure
Disease Progression
Retrospective Studies
Hypertension
Mortality

Keywords

  • Bisoprolol
  • Chronic obstructive pulmonary disease
  • Exacerbation
  • Heart failure
  • β-blocker

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Protective effects of bisoprolol against acute exacerbation in moderate-to-severe chronic obstructive pulmonary disease. / Taniguchi, Akihiko; Miyahara, Nobuaki; Oda, Naohiro; Morichika, Daisuke; Ichihara, Eiki; Ozed, Isao; Tanimoto, Yasushi; Ichikawa, Hirohisa; Fujii, Utako; Tanimoto, Mitsune; Kanehiro, Arihiko; Kiura, Katsuyuki.

In: Acta Medica Okayama, Vol. 71, No. 5, 2017, p. 453-457.

Research output: Contribution to journalArticle

Taniguchi, A, Miyahara, N, Oda, N, Morichika, D, Ichihara, E, Ozed, I, Tanimoto, Y, Ichikawa, H, Fujii, U, Tanimoto, M, Kanehiro, A & Kiura, K 2017, 'Protective effects of bisoprolol against acute exacerbation in moderate-to-severe chronic obstructive pulmonary disease', Acta Medica Okayama, vol. 71, no. 5, pp. 453-457.
Taniguchi, Akihiko ; Miyahara, Nobuaki ; Oda, Naohiro ; Morichika, Daisuke ; Ichihara, Eiki ; Ozed, Isao ; Tanimoto, Yasushi ; Ichikawa, Hirohisa ; Fujii, Utako ; Tanimoto, Mitsune ; Kanehiro, Arihiko ; Kiura, Katsuyuki. / Protective effects of bisoprolol against acute exacerbation in moderate-to-severe chronic obstructive pulmonary disease. In: Acta Medica Okayama. 2017 ; Vol. 71, No. 5. pp. 453-457.
@article{c3bfe9a99cda4dbe8bdc69c3ad4c1f03,
title = "Protective effects of bisoprolol against acute exacerbation in moderate-to-severe chronic obstructive pulmonary disease",
abstract = "Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure.",
keywords = "Bisoprolol, Chronic obstructive pulmonary disease, Exacerbation, Heart failure, β-blocker",
author = "Akihiko Taniguchi and Nobuaki Miyahara and Naohiro Oda and Daisuke Morichika and Eiki Ichihara and Isao Ozed and Yasushi Tanimoto and Hirohisa Ichikawa and Utako Fujii and Mitsune Tanimoto and Arihiko Kanehiro and Katsuyuki Kiura",
year = "2017",
language = "English",
volume = "71",
pages = "453--457",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "5",

}

TY - JOUR

T1 - Protective effects of bisoprolol against acute exacerbation in moderate-to-severe chronic obstructive pulmonary disease

AU - Taniguchi, Akihiko

AU - Miyahara, Nobuaki

AU - Oda, Naohiro

AU - Morichika, Daisuke

AU - Ichihara, Eiki

AU - Ozed, Isao

AU - Tanimoto, Yasushi

AU - Ichikawa, Hirohisa

AU - Fujii, Utako

AU - Tanimoto, Mitsune

AU - Kanehiro, Arihiko

AU - Kiura, Katsuyuki

PY - 2017

Y1 - 2017

N2 - Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure.

AB - Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure.

KW - Bisoprolol

KW - Chronic obstructive pulmonary disease

KW - Exacerbation

KW - Heart failure

KW - β-blocker

UR - http://www.scopus.com/inward/record.url?scp=85031097720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031097720&partnerID=8YFLogxK

M3 - Article

C2 - 29042706

AN - SCOPUS:85031097720

VL - 71

SP - 453

EP - 457

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 5

ER -